Unknown

Dataset Information

0

Clinical application of a lung cancer organoid (tumoroid) culture system.


ABSTRACT: Despite high expectations for lung tumoroids, they have not been applied in the clinic due to the difficulty of their long-term culture. Here, however, using AO (airway organoid) media developed by the Clevers laboratory, we succeeded in generating 3 lung tumoroid lines for long-term culture (>13 months) from 41 lung cancer cases (primary or metastatic). Use of nutlin-3a was key to selecting lung tumoroids that harbor mutant p53 in order to eliminate normal lung epithelial organoids. Next-generation sequencing (NGS) analysis indicated that each lung tumoroid carried BRAFG469A, TPM3-ROS1 or EGFRL858R/RB1E737*, respectively. Targeted therapies using small molecule drugs (trametinib/erlotinib for BRAFG469A, crizotinib/entrectinib for TPM3-ROS1 and ABT-263/YM-155 for EGFRL858R/RB1E737*) significantly suppressed the growth of each lung tumoroid line. AO media was superior to 3 different media developed by other laboratories. Our experience indicates that long-term lung tumoroid culture is feasible, allowing us to identify NGS-based therapeutic targets and determine the responsiveness to corresponding small molecule drugs.

SUBMITTER: Yokota E 

PROVIDER: S-EPMC8042017 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

2021-02-09 | GSE157659 | GEO
| PRJNA662339 | ENA
| S-EPMC9877297 | biostudies-literature
| S-EPMC5620133 | biostudies-other
| S-EPMC5589910 | biostudies-literature
| S-EPMC9138465 | biostudies-literature
| S-EPMC8504437 | biostudies-literature
| S-EPMC9736416 | biostudies-literature
| S-EPMC8273816 | biostudies-literature
| S-EPMC8664924 | biostudies-literature